Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Apple Turns 50: From Garage Startup to AI Crossroads 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
GAITHERSBURG, Md., Sept. 06, 2017 -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that Bill Enright, President and Chief Executive Officer of Altimmune, will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, taking place September 11-12 at the Lotte New York Palace Hotel in New York City.
Presentation Details
| Date: | Tuesday, September 12 |
| Time: | 10:25am Eastern Time |
| Location: | Lotte New York Palace Hotel, Kennedy I Ballroom |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.
Altimmune Contacts Bill Enright President and CEO Phone: 240-654-1450 Email: [email protected] Michael Rice Investor Relations Phone: 646-597-6979 Email: [email protected]
